MoonLake Immunotherapeutics Balance Sheet Health
Financial Health criteria checks 6/6
MoonLake Immunotherapeutics has a total shareholder equity of $530.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $544.9M and $14.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$519.80m |
| Equity | US$530.03m |
| Total liabilities | US$14.85m |
| Total assets | US$544.88m |
Recent financial health updates
Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
May 14
We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn
Jan 29Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
Oct 16Recent updates
MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward
Jul 18Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
May 14MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3
Feb 26We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn
Jan 29Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
Oct 16Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics
Jul 26Financial Position Analysis
Short Term Liabilities: MLTX's short term assets ($536.9M) exceed its short term liabilities ($12.3M).
Long Term Liabilities: MLTX's short term assets ($536.9M) exceed its long term liabilities ($2.6M).
Debt to Equity History and Analysis
Debt Level: MLTX is debt free.
Reducing Debt: MLTX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MLTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MLTX has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 3.2% each year.